Physician profile
Kyle Van Schwickerath
NPI 1245857101
$10,878.39
in general payments reported to CMS, 2019-2025
30 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $491 · 2021: $3,340 · 2022: $3,201 · 2023: $1,076 · 2024: $2,228 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328 · Travel and Lodging: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.82 |
| Travel and Lodging | $1,518.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alpha Orthopedic Systems | $4,260.95 | 2020-2022 | |
| Stryker Corporation | $2,261.88 | 2021-2023 | Variax, Ortholoc 2 Lapifuse, Anchorage |
| Vilex LLC | $1,911.79 | 2023-2024 | |
| Forthright Medical - Az, LLC | $486.90 | 2025 | Ossiofiber Trimmable Fixation Nail System, Cannulated |
| Integra Lifesciences Corporation | $453.36 | 2020-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $256.62 | 2021-2023 | Stravix, Grafix |
| Amgen INC. | $191.85 | 2024 | Otezla, Repatha, Evenity |
| Sanara Medtech INC. | $169.00 | 2023 | Celleraterx |
| Acera Surgical, INC. | $157.79 | 2021-2022 | |
| Organogenesis INC. | $124.74 | 2022 | |
| Depuy Synthes Sales INC. | $74.99 | 2021-2023 | Healix Knotless Peek |
| Bsn Medical INC | $47.11 | 2022 | |
| Dexcom, INC. | $40.97 | 2024 | Dexcom G6 Transmitter |
| Djo, LLC | $40.24 | 2025 | Cmf |
| Biowound Solutions, INC. | $39.66 | 2024 | Bio-Connekt |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $38.29 | 2023 | |
| Novo Nordisk INC | $38.08 | 2024 | Ozempic, Rybelsus |
| Mannkind Corporation | $31.39 | 2024 | |
| Bone Support INC. | $30.81 | 2022 | |
| Osteomed LLC | $30.17 | 2021 | |
| Lilly USA, LLC | $28.32 | 2024 | Zepbound, Mounjaro |
| Abbvie INC. | $27.33 | 2024 | |
| Xeris Pharmaceuticals, INC. | $21.98 | 2024 | Recorlev |
| Verity Pharmaceuticals INC. | $20.98 | 2024 | Tlando |
| Acumed LLC | $17.87 | 2021 | |
| Globus Medical, INC. | $16.06 | 2025 | Precice® Intramedullary Limb Lengthening System |
| Ibsa Pharma INC. | $15.16 | 2024 | Tirosint, Licart |
| Paratek Pharmaceuticals, INC. | $15.04 | 2024 | Nuzyra |
| Kerecis Limited | $14.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.07 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Schwickerath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.